You can:
Name | Alpha-2A adrenergic receptor |
---|---|
Species | Homo sapiens (Human) |
Gene | ADRA2A |
Synonym | alpha2D alpha2A-AR alpha2A-adrenoceptor alpha2A-adrenergic receptor alpha2A [ Show all ] |
Disease | Attention deficit hyperactivity disorder Sexual dysfunction Pain |
Length | 450 |
Amino acid sequence | MGSLQPDAGNASWNGTEAPGGGARATPYSLQVTLTLVCLAGLLMLLTVFGNVLVIIAVFTSRALKAPQNLFLVSLASADILVATLVIPFSLANEVMGYWYFGKAWCEIYLALDVLFCTSSIVHLCAISLDRYWSITQAIEYNLKRTPRRIKAIIITVWVISAVISFPPLISIEKKGGGGGPQPAEPRCEINDQKWYVISSCIGSFFAPCLIMILVYVRIYQIAKRRTRVPPSRRGPDAVAAPPGGTERRPNGLGPERSAGPGGAEAEPLPTQLNGAPGEPAPAGPRDTDALDLEESSSSDHAERPPGPRRPERGPRGKGKARASQVKPGDSLPRRGPGATGIGTPAAGPGEERVGAAKASRWRGRQNREKRFTFVLAVVIGVFVVCWFPFFFTYTLTAVGCSVPRTLFKFFFWFGYCNSSLNPVIYTIFNHDFRRAFKKILCRGDRKRIV |
UniProt | P08913 |
Protein Data Bank | N/A |
GPCR-HGmod model | P08913 |
3D structure model | This predicted structure model is from GPCR-EXP P08913. |
BioLiP | N/A |
Therapeutic Target Database | T11448 |
ChEMBL | CHEMBL1867 |
IUPHAR | 25 |
DrugBank | BE0000289 |
Name | Yohimbine |
---|---|
Molecular formula | C21H26N2O3 |
IUPAC name | methyl (1S,15R,18S,19R,20S)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate |
Molecular weight | 354.45 |
Hydrogen bond acceptor | 4 |
Hydrogen bond donor | 2 |
XlogP | 2.9 |
Synonyms | KBioSS_000576 2Y49VWD90Q methyl hydroxy[?]carboxylate AKOS015902024 NCGC00025018-10 [ Show all ] |
Inchi Key | BLGXFZZNTVWLAY-SCYLSFHTSA-N |
Inchi ID | InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15-,17-,18-,19+/m0/s1 |
PubChem CID | 8969 |
ChEMBL | CHEMBL15245 |
IUPHAR | 102 |
BindingDB | 50013515, 50203564 |
DrugBank | DB01392 |
Structure | |
Lipinski's druglikeness | This ligand satisfies Lipinski's rule of five. |
Parameter | Value | Reference | Database source |
---|---|---|---|
N/A | N/A | DrugBank | |
EC50 | 8.5 nM | PMID16562853 | BindingDB,ChEMBL |
IC50 | 3.67 nM | PMID19788200 | BindingDB |
IC50 | 6.151 nM | DrugMatrix in vitro pharmacology data | ChEMBL |
IC50 | 8.4 nM | PMID23403082 | ChEMBL |
Inhibition | -5.0 % | PMID23403082 | ChEMBL |
Ki | 0.32 nM | PMID1353247 | BindingDB |
Ki | 0.42 nM | PMID10762040 | ChEMBL |
Ki | 0.42 nM | PMID10762040 | BindingDB |
Ki | 0.43 nM | PMID7908054 | BindingDB |
Ki | 0.44 nM | PMID1353247, PMID1656026 | BindingDB |
Ki | 0.5 nM | PMID1353247 | BindingDB |
Ki | 0.61 nM | PMID7908054 | BindingDB |
Ki | 0.630958 - 3.98108 nM | PMID7996470, PMID1353247, PMID7908642 | IUPHAR |
Ki | 0.65 nM | PMID1353247, PMID1656026 | BindingDB |
Ki | 0.71 nM | PMID9400006 | BindingDB |
Ki | 1.2 nM | PMID9605427 | BindingDB |
Ki | 1.4 nM | PMID15911252 | ChEMBL |
Ki | 1.6 nM | PMID11408545, PMID6149136 | BindingDB |
Ki | 1.8 nM | PMID17257841 | BindingDB |
Ki | 2.307 nM | DrugMatrix in vitro pharmacology data | ChEMBL |
Ki | 2.5 nM | PMID11132243 | BindingDB |
Ki | 2.7 nM | PMID6149136 | BindingDB |
Ki | 3.1 nM | PMID23403082, PMID10602703 | BindingDB,ChEMBL |
Ki | 3.16 nM | PMID10611634 | BindingDB |
Ki | 3.5 nM | PMID11408545 | BindingDB |
Ki | 3.6 nM | PMID7855217 | BindingDB |
Ki | 3.71 nM | PMID7996470 | BindingDB |
Ki | 3.76 nM | PMID7996470 | BindingDB |
Ki | 6.3 nM | PMID10611634 | BindingDB |
Ki | 7.5 nM | PMID7562902 | BindingDB,ChEMBL |
Ki | 7.94 nM | PMID10611634 | BindingDB |
Ki | 132.0 nM | PMID1656026 | BindingDB |
zhanglabzhanggroup.org | +65-6601-1241 | Computing 1, 13 Computing Drive, Singapore 117417